Quotes 5-day view Delayed Nasdaq
02/25/2021
02/26/2021
03/01/2021
03/02/2021
03/03/2021
Date
8.01(c)
7.97(c)
8.52(c)
10.72(c)
9.89(c)
Last
1 668 035
737 316
779 879
2 164 386
2 002 828
Volume
-13.03% -0.50% +6.90% +25.82% -7.74% Change
Sales 2020
-
-
-
Net income 2020
-87,8 M - -
Net cash position 2020
60,6 M - -
P/E ratio 2020
-6,01x
Yield 2020
-
Sales 2021
-
-
-
Net income 2021
-109 M - -
Net cash position 2021
180 M - -
P/E ratio 2021
-8,87x
Yield 2021
-
Capitalization
651 M 651 M -
EV / Sales 2020
-
EV / Sales 2021
-
Nbr of Employees
121
Free-Float
49,8%
Solid Biosciences Inc., formerly Solid Biosciences, LLC, is a life science company. The Company is focused on developing therapies for duchenne muscular dystrophy (DMD). It is developing gene therapies, disease modifying therapies and assistive devices, all targeting the various facets of the DMD. Its corrective therapies platform is engaged in the development of gene therapy candidates for DMD. Its lead program,...
Notations Surperformance© of Solid Biosciences Inc.
Trading Rating : Investor Rating : -
All news about SOLID BIOSCIENCES INC.
News in other languages on SOLID BIOSCIENCES INC.
- No features available -
Analyst Recommendations on SOLID BIOSCIENCES INC.
Chart SOLID BIOSCIENCES INC.
Duration :
Auto.
2 months
3 months
6 months
9 months
1 year
2 years
5 years
10 years
Max.
Period :
Day
Week
Technical analysis trends SOLID BIOSCIENCES INC.
Short Term Mid-Term Long Term Trends Bullish Bullish Bullish
Income Statement Evolution
Please enable JavaScript in your browser's settings to use dynamic charts.
Mean consensus
HOLD
Number of Analysts
6
Average target price
6,70 $
Last Close Price
9,89 $
Spread / Highest target
26,4%
Spread / Average Target
-32,3%
Spread / Lowest Target
-79,8%
Please enable JavaScript in your browser's settings to use dynamic charts.
Canada
Deutschland
España
France
Italia
Schweiz (DE)
United Kingdom
Report
